CapWealth Advisors LLC Sells 2,707 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

CapWealth Advisors LLC lessened its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 174,142 shares of the biopharmaceutical company’s stock after selling 2,707 shares during the period. Bristol-Myers Squibb makes up approximately 1.4% of CapWealth Advisors LLC’s investment portfolio, making the stock its 26th largest position. CapWealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $11,178,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BMY. BlackRock Inc. boosted its holdings in shares of Bristol-Myers Squibb by 6.7% during the second quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after acquiring an additional 7,178,698 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Bristol-Myers Squibb by 42.5% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,527,341 shares of the biopharmaceutical company’s stock valued at $671,013,000 after buying an additional 3,140,646 shares during the period. Swiss National Bank boosted its stake in shares of Bristol-Myers Squibb by 36.2% in the fourth quarter. Swiss National Bank now owns 7,494,688 shares of the biopharmaceutical company’s stock valued at $481,084,000 after buying an additional 1,992,824 shares during the period. Railway Pension Investments Ltd boosted its stake in shares of Bristol-Myers Squibb by 387.3% in the third quarter. Railway Pension Investments Ltd now owns 2,067,698 shares of the biopharmaceutical company’s stock valued at $104,852,000 after buying an additional 1,643,409 shares during the period. Finally, California Public Employees Retirement System boosted its stake in shares of Bristol-Myers Squibb by 24.3% in the fourth quarter. California Public Employees Retirement System now owns 7,827,076 shares of the biopharmaceutical company’s stock valued at $502,420,000 after buying an additional 1,532,029 shares during the period. Institutional investors own 84.33% of the company’s stock.

Several brokerages recently issued reports on BMY. Wolfe Research set a $66.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, November 1st. Gabelli began coverage on Bristol-Myers Squibb in a research note on Wednesday, November 27th. They issued a “buy” rating for the company. UBS Group boosted their price target on Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research note on Wednesday, October 23rd. Mizuho began coverage on Bristol-Myers Squibb in a research note on Monday, November 25th. They issued a “buy” rating for the company. Finally, Citigroup upgraded Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price target for the company in a research note on Monday, January 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Buy” and an average target price of $61.69.

Shares of BMY opened at $66.08 on Friday. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $68.34. The company has a market cap of $109.02 billion, a P/E ratio of 30.17, a P/E/G ratio of 1.29 and a beta of 0.76. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. The firm has a 50 day simple moving average of $64.96 and a two-hundred day simple moving average of $55.92.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.22 EPS for the quarter, beating the consensus estimate of $0.88 by $0.34. Bristol-Myers Squibb had a net margin of 13.15% and a return on equity of 48.97%. The business had revenue of $7.95 billion during the quarter, compared to the consensus estimate of $6.20 billion. During the same period in the previous year, the business earned $0.94 earnings per share. The company’s revenue was up 33.0% on a year-over-year basis. On average, analysts expect that Bristol-Myers Squibb Co will post 6.16 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were given a dividend of $0.45 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 annualized dividend and a yield of 2.72%. The ex-dividend date was Thursday, January 2nd. Bristol-Myers Squibb’s payout ratio is currently 38.38%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Outstanding Shares, Buying and Selling Stocks

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.